【ChiCTR2500114608】Implementation of biomimetic 3D bioprinting technology in selecting optimal regimens as adjuvant therapy to prevent hepatocellular carcinoma recurrence after liver resection or ablation: a feasibility study

查看原文

立即下载

基本信息

登记号

ChiCTR2500114608

试验状态

正在进行

药物名称

药物类型

规范名称

首次公示信息日的期

2025-12-15

临床申请受理号

靶点

适应症

Liver cancer

试验通俗题目

Implementation of biomimetic 3D bioprinting technology in selecting optimal regimens as adjuvant therapy to prevent hepatocellular carcinoma recurrence after liver resection or ablation: a feasibility study

试验专业题目

申办单位信息

申请人联系人

请登录查看

申请人名称

请登录查看

联系人邮箱

请登录查看

联系人邮编

联系人通讯地址

请登录查看

临床试验信息

试验目的

To evaluate the efficacy of biomimetic 3D bioprinting technology in guiding the selection of optimal adjuvant treatment regimens to prevent hepatocellular carcinoma (HCC) recurrence after curative liver resection.

试验分类

请登录查看

试验类型

病例研究

试验分期

其它

随机化

None

盲法

试验项目经费来源

None

试验范围

目标入组人数

实际入组人数

第一例入组时间

2025-12-15

试验终止时间

2030-12-31

是否属于一致性

入选标准

1. Age >= 18 years at the time of screening; 2.Diagnosis of HCC; 3.Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; 4. With or without prior locoregional therapy such as transarterial chemoembolisation (TACE), radiofrequency ablation (RFA), and stereotactic body radiation therapy (SBRT) before surgery; 5.Meet any item indicating higher risk of tumour recurrence: any tumour size >= 5cm, number of tumour >= 3, presence of microvascular or marcovascular invasion, or poor tumour differentiation; 6.No prior systemic therapy for HCC; 7. No other active malignancies within 5 years, except malignancies with a negligible risk of metastasis or death (eg. 5-year overall survival rate > 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or stage I uterine cancer; 8. Willing and able to provide written informed consent for the collection and usage of biological samples.；

排除标准

1.Non-HCC diagnosis, including fibrolamellar HCC, sarcomatoid HCC, mixed HCC cholangiocarcinoma etc; 2.Fail to give consent or refusal to take part in the study; 3.Child-Pugh class C liver cirrhosis; 4.Receipt of any prior systemic therapy for HCC.；

研究者信息

研究负责人姓名

请登录查看

试验机构

Department of Surgery, The University of Hong Kong

研究负责人电话

请登录查看

研究负责人邮箱

请登录查看

研究负责人邮编

联系人通讯地址

请登录查看